The tumour-inhibiting potential of the progesterone antagonist Onapristone in the human mammary carcinoma T61 in nude mice
Authors:
- 1 March 1992
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 118 (3) , 187-189
Abstract
The progesterone antagonist Onapristone proved to possess strong tumour-inhibiting activity in a panel of experimental mammary carcinomas. Its underlying mechanism of action is due to a progesterone-receptor-mediated induction of terminal differentiation and a specific blockade of the cell cycle and is also present in the absence of progesterone as was shown in the MXT mammary tumour. To prove this further, the tumour-inhibiting activity of Onapristone was investigated in the human postmenopausal T61 mammary tumour implanted in castrated male nude mice. Whereas Onapristone given alone had no effect on growth of established tumours, after stimulation of the relatively low progesterone receptor content of this tumour line with an oestrogen, Onapristone significantly inhibited tumour growth. Thus, we suggest that Onapristone exerts its antitumour action via progesterone receptors. As there is no endogenous progesterone in these mice, the tumour-inhibiting activity of Onapristone is not primarily due to a classical antihormonal effect.Keywords
This publication has 15 references indexed in Scilit:
- Progesterone antagonists block the growth of experimental mammary tumors in G0/G1Breast Cancer Research and Treatment, 1990
- Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer modelsThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: Mechanistic studiesBreast Cancer Research and Treatment, 1989
- Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the ratEuropean Journal of Cancer and Clinical Oncology, 1989
- The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell deathJournal of Steroid Biochemistry, 1989
- Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cellsBreast Cancer Research and Treatment, 1987
- Characterization of the T61 human breast carcinoma established in nude miceEuropean Journal of Cancer and Clinical Oncology, 1985
- Endocrine sensitivity of the receptor-positive T61 human breast carcinoma serially grown in nude miceInternational Journal of Cancer, 1985
- New steroids with antiprogestational and antiglucocorticoid activitiesSteroids, 1984
- Criteria for the Establishment of a Double-Labeling Assay for Simultaneous Determination of Estrogen and Progesterone ReceptorsOncology, 1984